SecSonar.com

Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Vanda Pharmaceuticals Inc. (VNDA) is a Biotechnology company based in US with a market capitalization of $391.5M. Revenue grew 8.7% year-over-year and free cash flow was negative at -$110.4M. This page tracks VNDA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 368 employees · IPO Apr 12, 2006

Valuation

Valuation & price

$6.28 · as of May 17, 2026 · -34.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.20

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$9.56$6.88$4.20Jul 25Dec 25Jun 26Jul 7, 25$4.89Jul 9, 25$5.02Jul 11, 25$4.74Jul 15, 25$4.76Jul 17, 25$4.86Jul 21, 25$4.66Jul 23, 25$4.84Jul 25, 25$4.74Jul 29, 25$4.68Jul 31, 25$4.26Aug 4, 25$4.26Aug 6, 25$4.22Aug 8, 25$4.20Aug 12, 25$4.31Aug 14, 25$4.43Aug 18, 25$4.56Aug 20, 25$4.60Aug 22, 25$4.75Aug 27, 25$4.62Aug 29, 25$4.73Sep 3, 25$4.72Sep 5, 25$4.61Sep 9, 25$4.51Sep 11, 25$4.60Sep 15, 25$4.38Sep 17, 25$4.39Sep 19, 25$4.49Sep 23, 25$4.76Sep 25, 25$4.83Sep 29, 25$4.91Oct 1, 25$5.10Oct 3, 25$5.43Oct 7, 25$5.32Oct 9, 25$5.45Oct 13, 25$5.23Oct 16, 25$5.27Oct 20, 25$5.33Oct 22, 25$5.34Oct 24, 25$5.50Oct 28, 25$5.58Oct 30, 25$4.32Nov 3, 25$4.47Nov 5, 25$4.44Nov 7, 25$4.40Nov 11, 25$4.38Nov 13, 25$4.34Nov 17, 25$4.40Nov 19, 25$5.14Nov 21, 25$4.80Nov 25, 25$5.00Nov 28, 25$5.36Dec 2, 25$4.92Dec 5, 25$5.39Dec 9, 25$6.06Dec 11, 25$6.60Dec 15, 25$6.63Dec 17, 25$6.82Dec 19, 25$6.75Dec 23, 25$6.84Dec 26, 25$7.04Dec 30, 25$7.03Jan 2, 26$8.25Jan 6, 26$8.13Jan 8, 26$7.34Jan 12, 26$7.41Jan 14, 26$7.70Jan 16, 26$7.47Jan 21, 26$7.93Jan 23, 26$8.01Jan 28, 26$7.69Jan 30, 26$7.54Feb 3, 26$8.05Feb 5, 26$7.23Feb 9, 26$7.51Feb 11, 26$7.43Feb 13, 26$6.09Feb 18, 26$6.03Feb 20, 26$5.76Feb 24, 26$8.17Feb 26, 26$8.60Mar 2, 26$8.17Mar 4, 26$8.20Mar 6, 26$7.89Mar 10, 26$9.56Mar 12, 26$9.29Mar 16, 26$8.81Mar 19, 26$8.57Mar 23, 26$7.00Mar 25, 26$7.25Mar 27, 26$6.91Mar 31, 26$6.91Apr 2, 26$7.00Apr 7, 26$7.45Apr 9, 26$7.33Apr 13, 26$7.16Apr 15, 26$7.27Apr 17, 26$7.27Apr 21, 26$6.78Apr 23, 26$6.69Apr 27, 26$6.79Apr 29, 26$7.05May 1, 26$7.00May 5, 26$7.39May 8, 26$6.28May 12, 26$6.42May 14, 26$6.39May 18, 26$6.08May 20, 26$6.18May 22, 26$6.19May 27, 26$6.46May 29, 26$6.45Jun 2, 26$6.13Jun 4, 26$6.25Jun 8, 26$5.94Jun 10, 26$6.03Jun 12, 26$5.87Jun 16, 26$5.73Jun 18, 26$5.80Jun 23, 26$5.95Jun 29, 26$6.14
$4.1952-week range$9.56
Loading valuation history…

Fundamentals

Key fundamentals

$391.5M

Market cap

8.7%

Revenue growth (YoY)

94.0%

Gross margin

-$110.4M

Free cash flow (USD)

-$251.2M

Net debt

Net cash position

1.3%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$146.0MFY 2017$165.1MFY 2018$193.1MFY 2019$227.2MFY 2020$248.2MFY 2021$268.7MFY 2022$254.4MFY 2023$192.6MFY 2024$198.8MFY 2025$216.1M
$146M$216.1M

Free cash flow by year

2016 → 2025

FY 2016$-9.5MFY 2017$-3.6MFY 2018$4.6MFY 2019$44.9MFY 2020$50.0MFY 2021$63.7MFY 2022$31.3MFY 2023$12.4MFY 2024$-16.2MFY 2025$-110.4M
-$9.5M-$110.4M

Gross margin by year

2021 → 2025

FY 202190.5%FY 202290.5%FY 202392.3%FY 202494.3%FY 202594.0%
90.5%94.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 5, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • 8-K eventDirector AppointmentApr 22, 2026Filing
  • 8-K eventExecutive ResignationApr 2, 2026Filing

Questions

Frequently asked questions

What is Vanda Pharmaceuticals Inc.'s market cap?

Vanda Pharmaceuticals Inc. (VNDA) has a market capitalization of $391.5M.

What is VNDA's P/E ratio?

A meaningful P/E ratio is not available for VNDA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is VNDA's price-to-book (P/B) ratio?

VNDA trades at 1.20 times book value per share.

Are insiders buying VNDA stock?

SEC Form 4 filings show no open-market insider buys at Vanda Pharmaceuticals Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

XFOR

X4 Pharmaceuticals, Inc.

$402.3M

FULC

Fulcrum Therapeutics, Inc.

$377.7M

LYEL

Lyell Immunopharma, Inc.

$406.2M

PTN

Palatin Technologies, Inc.

$368M

CCCC

C4 Therapeutics, Inc.

$367.8M

PALI

Palisade Bio, Inc.

$366.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.